About EXINI Diagnostics
EXINI Diagnostics is a company based in Lund (Sweden) founded in 1999 was acquired by Progenics in October 2015. It operates as a AI-as-a-Service and Professional Services. EXINI Diagnostics offers products and services including aPROMISE, aBSI, CURE8, PYLARIFY AI, and PYLCLARI AI. EXINI Diagnostics operates in a competitive market with competitors including Perspectum, Qure.ai, IXICO, Zebra Medical Vision and Deeptek, among others.
- Headquarter Lund, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exini Diagnostics Ab
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EXINI Diagnostics
EXINI Diagnostics offers a comprehensive portfolio of products and services, including aPROMISE, aBSI, CURE8, PYLARIFY AI, and PYLCLARI AI.
AI software for prostate cancer image analysis is provided.
Automated bone scan index analysis tool is offered here.
AI-based diagnostic imaging solution for cancer is developed.
AI tool for PSMA imaging in cancer is utilized.
Advanced AI for PSMA scan analysis is implemented.
Funding Insights of EXINI Diagnostics
Detailed funding history for EXINI Diagnostics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in EXINI Diagnostics
EXINI Diagnostics has secured backing from 1 investor. Prominent investors backing the company include Progenics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
|
Locked | Locked | Locked |
Investor details for EXINI Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EXINI Diagnostics
Investment portfolio details for EXINI Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EXINI Diagnostics
Detailed financials for EXINI Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exini Diagnostics Comparisons
Peer comparison for EXINI Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EXINI Diagnostics
EXINI Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Perspectum, Qure.ai, IXICO, Zebra Medical Vision and Deeptek, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Precision medicine software for liver disease diagnosis is offered.
|
|
| Locked | Locked | Locked |
AI-powered solutions for medical imaging diagnostics
|
|
| Locked | Locked | Locked |
AI-based medical image management and analysis solutions for healthcare organizations
|
|
| Locked | Locked | Locked |
Provider of AI and SaaS-based medical image based decision support tools
|
|
| Locked | Locked | Locked |
AI-augmented diagnostic tools for radiology imaging are developed.
|
|
| Locked | Locked | Locked |
AI-driven solutions for medical diagnostic imaging are developed.
|
Detailed competitors of EXINI Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exini Diagnostics
Complete news archive for EXINI Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EXINI Diagnostics
EXINI Diagnostics was founded in 1999.
EXINI Diagnostics is headquartered in Lund, Sweden.
EXINI Diagnostics is engaged in the development of AI-driven software for automated analysis of diagnostic images, focusing on areas such as PSMA, cardiac, brain, and bone scans. Solutions are provided to over 800 sites worldwide, primarily targeting precision oncology for prostate cancer. The company, a subsidiary of Lantheus Holdings, Inc., collaborates with healthcare professionals and industry partners to enhance medical imaging through advanced technology and data management expertise. Research and software development are key sectors of operation, with platforms integrated into major medical systems like Siemens Healthineers syngo.via.
EXINI Diagnostics's top competitors include Perspectum, Qure.ai and Deeptek.
EXINI Diagnostics offers aPROMISE, aBSI, CURE8, PYLARIFY AI, and PYLCLARI AI.
EXINI Diagnostics has 1 investor. Key investors include Progenics.